Dr. Yaning Wang is the Founder and CEO of Rui Ning Kang Pharma, providing consulting service for new drug discovery and development, dose optimization, trial design, biomarker/surrogate/clinical endpoints justification, regulatory interactions, IND/NDA/BLA package preparation, asset and company evaluation, and license in/out negotiation. Between 2021 and 2024, he was the CEO of Createrna, a clinical-stage biopharmaceutical company developing novel therapeutics for multiple diseases. Under his leadership, 500 million RMB was raised during a capital-winter period and multiple billion-dollar license-out deals were achieved. Before 2021, he was the Director of the Division of Pharmacometrics at US FDA and oversaw reviews, research projects, and policy development for all disease areas. Before joining FDA, Dr. Wang received his Ph.D. in Pharmaceutics and master’s degree in Statistics from the University of Florida in 2003. He also obtained a master’s degree in Biochemistry (1999) from National Doping Control Center and a bachelor’s degree in Pharmacy (1996) from Peking University in China. Dr. Wang is an Adjunct Professor in University of Florida, Beijing University, Shanghai University of Traditional Chinese Medicine, and Central South University. Dr. Wang has published over 120 papers and given over 500 presentations at various national and international meetings as an expert in new drug development and regulation. He was selected to be one of the top Healthcare Technology Leaders of Washington, DC for 2023. He is the external advisor for Chinese National Medical Products Administration and the expert reviewer for Chinese Ministry of Science and Technology. He also serves as an expert advisor for Shanghai Free Trade Zone Fund and a senior consultant to multiple American investment companies and banks.